Research dossier
Clinical research on Mineral Pitch
9 trials reviewed across 7 indications.
Strongest evidence
Testosterone in middle-aged men
Mechanism
Proposed mechanisms include HPG-axis modulation via fulvic acid and dibenzo-α-pyrone signalling, Leydig-cell antioxidant protection, and improved mitochondrial steroidogenic capacity. The molecular story is plausible but not fully resolved in humans.
One industry-funded double-blind RCT (Pandit 2016, n=75) found 500 mg/day PrimaVie raised total testosterone ~20% over 90 days in healthy men aged 45–55. Biswas 2010 in oligospermic men showed a similar +24% testosterone signal. Both trials are small, single-site, manufacturer-supported, and run in narrow populations.
Effect documented in men 45–55 with low-normal baseline testosterone and in oligospermic infertile men. There is no RCT in healthy young men, where the 'TikTok testosterone booster' use case lives. Extrapolation across decades and across baseline T strata is not supported by trial data.
Trials cited
Pandit — purified Shilajit on testosterone in healthy men aged 45–55
positive · RCT
Pandit S, Biswas S, Jana U, De RK, Mukhopadhyay SC, Biswas TK, 2016, Andrologian=75Industry-fundedDouble-blind RCT in 75 healthy middle-aged men. 500 mg/day PrimaVie raised total testosterone ~20% (399 → 475 ng/dL, p<0.05) and free testosterone ~19% vs placebo over 90 days. DHEAS rose; LH and FSH unchanged. This is THE trial behind every 'shilajit boosts testosterone' claim online.
Narrow population (men 45–55, baseline T already on the low-normal side), single Indian site, manufacturer (Natreon) funding. The result has not been independently replicated in healthy young men, where the 'TikTok testosterone' framing is aimed.
Biswas — processed Shilajit for oligospermia
positive · RCT
Biswas TK, Pandit S, Mondal S, Biswas SK, Jana U, Ghosh T, Tripathi PC, Debnath PK, Auddy RG, Auddy B, 2010, Andrologian=35Industry-funded35 oligospermic men on 200 mg/day processed Shilajit for 90 days. Total sperm count +61% (p<0.001), motility +12–17%, normal morphology +19%, and testosterone +24% vs baseline. Reproductive markers MDA fell; semen fructose rose. Frequently cited as 'shilajit fixes fertility'.
Single-arm against baseline rather than a clean placebo comparison — some reports describe this as open-label. Small sample, single site, manufacturer-affiliated authors. The population (oligospermic men) is not the population using shilajit on social media.
Sperm parameters and male fertility
Mechanism
Antioxidant protection of sperm membranes from oxidative damage and possible HPG-axis support are the leading mechanistic candidates. Reductions in seminal MDA (a lipid-peroxidation marker) have been reported in trials.
Biswas 2010 reported large gains in sperm count (+61%), motility, and normal morphology in 35 oligospermic men over 90 days. The effect size is impressive on paper; the methodology (single-arm, single-site, industry-affiliated) means it should be read as a signal, not a confirmed result.
Demonstrated only in men with documented oligospermia. Routine 'fertility insurance' in fertile men has no supporting trial evidence. Couples evaluating fertility should pursue a reproductive endocrinology workup, not self-treat with shilajit.
Biswas — processed Shilajit for oligospermia
positive · RCT
Biswas TK, Pandit S, Mondal S, Biswas SK, Jana U, Ghosh T, Tripathi PC, Debnath PK, Auddy RG, Auddy B, 2010, Andrologian=35Industry-funded35 oligospermic men on 200 mg/day processed Shilajit for 90 days. Total sperm count +61% (p<0.001), motility +12–17%, normal morphology +19%, and testosterone +24% vs baseline. Reproductive markers MDA fell; semen fructose rose. Frequently cited as 'shilajit fixes fertility'.
Single-arm against baseline rather than a clean placebo comparison — some reports describe this as open-label. Small sample, single site, manufacturer-affiliated authors. The population (oligospermic men) is not the population using shilajit on social media.
Strength recovery and connective-tissue support
Mechanism
Skeletal-muscle biopsies after 500 mg/day PrimaVie showed enhanced exercise-induced upregulation of collagen and extracellular-matrix genes (Das 2016). The proposed phenotype is improved connective-tissue resilience, not direct hypertrophy.
Keller 2019 (n=63 active men) showed less strength decline after a fatigue protocol in the high-dose (500 mg/day) PrimaVie subgroup, with mixed results in the full cohort. Das 2016 (n=16) showed gene-expression shifts consistent with connective-tissue support. The clinical effect is modest, subgroup-driven, and industry-funded.
Useful framing: a potential connective-tissue and recovery adjunct, not a testosterone-driven mass builder. Trained athletes should expect small effects; novices should expect their resistance program to dominate any supplement effect.
Keller — Shilajit for fatigue-induced strength loss in trained men
mixed · RCT
Keller JL, Housh TJ, Hill EC, Smith CM, Schmidt RJ, Johnson GO, 2019, Journal of the International Society of Sports Nutritionn=63Industry-funded63 recreationally active men randomized to 250 mg/day PrimaVie, 500 mg/day PrimaVie, or placebo for 8 weeks. The high-dose group preserved MVIC strength after a fatigue protocol in the upper-50th-percentile subgroup; the overall main effect was weaker and serum hydroxyproline trends suggested reduced connective-tissue breakdown. No effect on baseline strength gains.
Subgroup-driven positive signal; primary endpoints in the full cohort were modest. Industry-supported (Natreon). Trial measures recovery/strength preservation, not testosterone or hypertrophy.
Das — Shilajit and skeletal-muscle transcriptome
mixed · RCT
Das A, Datta S, Rhea B, Sinha M, Veeraragavan M, Gordillo G, Roy S, 2016, Journal of Medicinal Foodn=16Industry-fundedTiny mechanistic RCT (n=16) using pre- and post-supplementation muscle biopsies. After 8 weeks of 500 mg/day PrimaVie, exercise-induced upregulation of collagen and extracellular-matrix gene-expression was more pronounced versus pre-supplementation. Provides the molecular hook for 'shilajit supports connective tissue.'
Sample size is too small for clinical conclusions. Endpoint is gene expression in biopsies, not strength, hypertrophy, or injury rate. Industry-funded by Natreon.
Fatigue and energy
Mechanism
Dibenzo-α-pyrones in shilajit are proposed to act as endogenous electron carriers supporting mitochondrial complexes I and II, with downstream effects on ATP production. The mechanism is consistent with anti-fatigue effects in animal models.
The 'shilajit for energy and fatigue' positioning rests almost entirely on a rat chronic-fatigue model (Surapaneni 2012) and mechanistic mitochondrial work. There is no adequately powered human RCT showing supplemental shilajit reduces fatigue in healthy adults or in chronic-fatigue patients.
Don't expect a felt energy lift in a non-deficient adult. The marketing framing is mechanistic extrapolation; the human-trial evidence base is essentially absent.
Surapaneni — Shilajit in a rat model of chronic fatigue
positive · Observational
Surapaneni DK, Adapa SR, Preeti K, Teja GR, Veeraragavan M, Krishnamurthy S, 2012, Journal of EthnopharmacologyAnimal study often cited as the 'shilajit fatigue' evidence on consumer sites. Processed shilajit reversed CFS-induced immobility and HPA-axis disruption and improved mitochondrial bioenergetic markers in rats. Mechanistically supportive of the fatigue narrative — but a rat model, not a human RCT.
Preclinical rat study, not a human fatigue RCT. There is no clean, adequately powered human trial of shilajit for fatigue. The marketing claim outruns the human evidence.
Cognition and Alzheimer's-related markers
Mechanism
Fulvic acid disrupts tau-protein self-aggregation and fibril formation in cell and animal models. The hypothesis is that crossing the BBB might translate to slower tau-related cognitive decline. Human translation is unproven.
The cognitive story is built from mechanistic in-vitro and animal work plus one combination-product Alzheimer's trial (BrainUp-10, shilajit + B-vitamins, n=82) reporting reduced apathy and cognitive stabilisation. The combination design means the shilajit-specific contribution cannot be isolated.
No standalone-shilajit RCT in healthy adults or in mild cognitive impairment exists. Treat cognitive claims as mechanistic hope, not validated treatment. Standard dementia care should not be deferred for shilajit.
Carrasco-Gallardo — Shilajit and fulvic acid as Alzheimer's nutraceutical
mixed · Systematic review
Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB, 2012, Archives of Medical ResearchNarrative review arguing that fulvic acid disrupts tau aggregation in cell and animal models and that a shilajit + B-vitamin formulation showed early promise in pilot work. Frequently cited as evidence shilajit 'helps cognition' — it is a review of mechanism, not a clinical efficacy verdict.
Narrative review, not a systematic meta-analysis. The human data referenced is pilot-level and uses a multi-ingredient formulation, not shilajit alone.
Guzmán-Martínez — BrainUp-10 (shilajit + B-vitamins) in Alzheimer's
mixed · RCT
Guzmán-Martínez L, Calfío C, Farías GA, Vilches C, Prieto R, Maccioni RB, 2021, Journal of Alzheimer's Diseasen=82Industry-fundedPhase II multicentre RCT of BrainUp-10 (shilajit + B-vitamins) in 82 mild-to-moderate Alzheimer's patients. The formulation arm reported reductions in apathy and stabilised cognitive scores versus placebo. The trial is the cleanest human cognition data near shilajit — but the product is a multi-ingredient combination.
Combination product — the cognition signal cannot be attributed to shilajit alone. B-vitamins (B6, B9, B12) independently affect cognition in some populations. Small Alzheimer's cohort; longer replication trials are not yet published.
Mitochondrial and antioxidant support
Mechanism
Fulvic acid functions as a low-molecular-weight humic substance with free-radical scavenging and metal-chelating properties. Dibenzo-α-pyrones are proposed mitochondrial electron carriers improving complex I/II efficiency.
The 'mitochondrial fuel' story is the most novel mechanistic angle shilajit has, and it is genuinely interesting at the chemistry level. Translation to hard clinical endpoints (energy, fatigue, exercise capacity, healthspan) is largely absent in human trials.
Mechanistically interesting; clinically unproven. Anyone reaching for shilajit specifically as 'mitochondrial support' is buying mechanism, not outcomes.
Das — Shilajit and skeletal-muscle transcriptome
mixed · RCT
Das A, Datta S, Rhea B, Sinha M, Veeraragavan M, Gordillo G, Roy S, 2016, Journal of Medicinal Foodn=16Industry-fundedTiny mechanistic RCT (n=16) using pre- and post-supplementation muscle biopsies. After 8 weeks of 500 mg/day PrimaVie, exercise-induced upregulation of collagen and extracellular-matrix gene-expression was more pronounced versus pre-supplementation. Provides the molecular hook for 'shilajit supports connective tissue.'
Sample size is too small for clinical conclusions. Endpoint is gene expression in biopsies, not strength, hypertrophy, or injury rate. Industry-funded by Natreon.
Surapaneni — Shilajit in a rat model of chronic fatigue
positive · Observational
Surapaneni DK, Adapa SR, Preeti K, Teja GR, Veeraragavan M, Krishnamurthy S, 2012, Journal of EthnopharmacologyAnimal study often cited as the 'shilajit fatigue' evidence on consumer sites. Processed shilajit reversed CFS-induced immobility and HPA-axis disruption and improved mitochondrial bioenergetic markers in rats. Mechanistically supportive of the fatigue narrative — but a rat model, not a human RCT.
Preclinical rat study, not a human fatigue RCT. There is no clean, adequately powered human trial of shilajit for fatigue. The marketing claim outruns the human evidence.
Mineral and fulvic-acid matrix
Mechanism
Shilajit is a mineral-rich exudate containing fulvic acid, humic acids, dibenzo-α-pyrones, and trace minerals including iron, magnesium, potassium, calcium, copper, and zinc. The trace-mineral profile is real but the contribution to systemic mineral status is unquantified at supplemental doses.
The 'complex mineral matrix' positioning is true at the chemistry level: shilajit does contain trace minerals and a distinctive fulvic-humic acid fraction. Whether 200–500 mg/day meaningfully shifts mineral status in a fed adult is not characterised by trials. As a 'multivitamin', shilajit is not a serious option.
Not a replacement for a basic multivitamin in someone with documented deficiencies. The mineral story is real chemistry, weak clinical translation.
Honest-evidence ledger — 2 trials that didn’t move the needle
Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.
Aldakheel — heavy-metal contamination in commercial shilajit samples
negative · Observational
Aldakheel RK, Gondal MA, Nasr MM, Dastageer MA, Almessiere MA, 2022, Biological Trace Element Researchn=2Multi-modal elemental analysis of commercial shilajit samples. Both Indian and Pakistani samples exceeded permissible regulatory limits for combinations of lead, arsenic, mercury, chromium, nickel, aluminium, strontium, manganese, barium, zinc, and boron. Indian samples were more contaminated overall. The 'consumer-grade raw resin' contamination concern is not theoretical.
Two samples is a snapshot, not a market survey. The qualitative finding — heavy metals in commercial shilajit at concerning levels — has been reproduced across multiple independent analytical reports and ConsumerLab testing.
Stohs — safety and efficacy of shilajit review
mixed · Systematic review
Stohs SJ, 2014, Phytotherapy ResearchToxicology and safety review concluding that purified, processed shilajit appears well-tolerated at studied doses (typically 200–500 mg/day), with the central caveat that raw, unprocessed shilajit can contain mycotoxins, free radicals, polymeric quinones, and heavy metals at unsafe levels. The 'purified vs raw' distinction is the safety story.
Narrative safety review, not a pooled efficacy meta-analysis. Stohs has historical industry consulting ties across the supplement sector; treat as a balanced safety overview rather than an independent regulatory verdict.
Are you deficient? Symptoms, risk groups, lab tests
Shilajit is not an essential nutrient. It is a mineral-rich resinous exudate from the Himalayas, Altai, Caucasus, and other high mountain ranges, used in Ayurvedic medicine for over 3,000 years as a rasayana (rejuvenator). There is no human dietary requirement, no RDA, and no recognised deficiency syndrome.
Common symptoms
- Not applicable — shilajit is not a deficiency-driven nutrient
- Listed only for cross-reference: shilajit is most commonly used by men in midlife seeking testosterone, recovery, or energy support, and by Ayurvedic practitioners as a broad-spectrum rasayana
Who is at risk
Men aged 45–55 with low-normal testosterone considering shilajit
The single RCT supporting the testosterone claim (Pandit 2016) enrolled exactly this population. Effect was ~20% rise in total T at 500 mg/day PrimaVie over 90 days. Verify a baseline serum total testosterone before starting; without a measurement, you cannot tell whether the supplement does anything.
Recreationally active men interested in recovery support
Keller 2019 (n=63) showed PrimaVie 500 mg/day partially preserved strength after a fatigue protocol in a subgroup. The signal is real but modest and subgroup-driven; the resistance training program will always dominate any supplement effect.
Healthy young men using shilajit for 'natural T boost'
The TikTok use case. There is NO RCT in healthy young men. Extrapolating from a trial in 45–55-year-olds with low-normal baseline T is not warranted. If you have not measured your testosterone, you are guessing about a baseline you do not know.
Women considering shilajit
Virtually all published trials are in men. Female use is essentially unstudied. Combined with documented heavy-metal contamination risk, the absence of female-specific safety data is meaningful. Avoid in pregnancy and breastfeeding entirely.
Side effects and drug interactions
Side effects
Heavy-metal contamination (raw / non-purified products)
Severe
The dominant safety concern. Independent analytical surveys (Aldakheel 2022 and consumer-laboratory testing) have repeatedly found commercial shilajit samples — particularly raw resin without third-party certification — exceeding regulatory limits for lead, arsenic, mercury, chromium, and nickel. Stohs 2014 and subsequent reviews frame purification (PrimaVie-style standardisation with COAs) as a non-negotiable safety baseline.
Worse with:raw shilajit resin, unpurified shilajit powder, unbranded shilajit
Gentler:PrimaVie® standardised purified shilajit with published heavy-metal COA
Iron loading and hemochromatosis risk
Severe
Shilajit is iron-rich. In adults with hereditary hemochromatosis, transfusion-related iron overload, or any iron-storage disorder, regular dosing risks accelerating iron accumulation.
Uric acid elevation and gout flares
Uncommon
Case-level reports and review summaries note hyperuricemia with longer-term shilajit dosing. Patients with gout, hyperuricaemia, or active urate-related kidney issues should avoid.
Mild GI upset, nausea, and headache
Common
Most commonly reported in trial datasets — generally mild and dose-related. Resolves with food or dose reduction. Typically uncommon at the 200–500 mg/day studied range.
Allergic reactions
Rare
Rare case reports of skin reactions and hypersensitivity to shilajit preparations. Stop and seek evaluation if rash, swelling, or breathing changes occur after starting.
Pregnancy and breastfeeding
Severe
No adequately powered human safety data in pregnancy. Combined with documented heavy-metal contamination risk in raw products, the precautionary call is straightforward: avoid throughout pregnancy and lactation.
Drug interactions
Additive effect
iron supplementsferrous sulfateferrous bisglycinateferrous gluconateShilajit is iron-rich and may also enhance non-haem iron absorption via fulvic-acid chelation. Stacking with iron supplementation can drive iron overload, particularly in genetically susceptible adults.
Do not stack shilajit with iron supplements unless directed by a clinician. Patients with low ferritin should be evaluated for the underlying cause rather than empirically iron-loading via shilajit.
Additive effect
warfarinDOACs (apixaban, rivaroxaban, dabigatran)aspirinclopidogrelShilajit has reported mild antiplatelet and coagulation-modulating activity in preclinical work. The signal is weak and inconsistent but case-level bleeding risk has been raised in safety reviews.
Avoid stacking with anticoagulants and antiplatelets without prescriber oversight. Discontinue at least 2 weeks before elective surgery or dental extraction.
Additive effect
testosterone replacement therapyanabolic steroidshCGIf the Pandit-2016 testosterone signal is real, stacking shilajit with exogenous androgens could compound effects. Clinically meaningful additive effects in TRT patients have not been characterised in trials.
Anyone on TRT should discuss shilajit with their prescribing clinician before starting. Independent monitoring of total/free testosterone, haematocrit, and PSA is appropriate.
Additive effect
antidiabetic medications (metformin, sulfonylureas, insulin, GLP-1 agonists)Animal and pilot human data suggest shilajit may modestly lower blood glucose. Stacked with prescription glucose-lowering therapy, additive hypoglycaemia is plausible.
Monitor home glucose for the first 2–4 weeks if combining. Adjust hypoglycaemic medication doses only under prescriber guidance.
Other
chemotherapeutic agentsimmunosuppressantsShilajit's antioxidant load could theoretically blunt the oxidative-stress mechanism of action of some chemotherapies. The interaction is theoretical but the precautionary principle applies in active oncology care.
Avoid shilajit during active chemotherapy unless explicitly cleared by the oncology team.
Other critical caveats
- Heavy-metal contamination is the dominant shilajit safety issue. Raw, unpurified, and uncertified shilajit products have repeatedly tested above regulatory limits for lead, arsenic, mercury, chromium, and nickel (Aldakheel 2022 and multiple consumer-laboratory reports). Use only third-party-tested, purified preparations — PrimaVie® or equivalent — with published certificates of analysis. Anonymous 'raw Himalayan resin' on social media is the highest-risk product class on the market.
- Avoid in pregnancy, breastfeeding, and active attempts to conceive. There is no adequately powered human pregnancy safety data, and the heavy-metal contamination risk makes the precautionary call straightforward. Female-specific safety data is essentially absent across the trial base.
- Avoid in hereditary hemochromatosis, transfusion-related iron overload, or any iron-storage disorder. Shilajit is iron-rich and fulvic acid may further enhance non-haem iron absorption. Routine ferritin monitoring is reasonable for adults using shilajit longer-term.
- Avoid in gout, hyperuricaemia, and urate-related kidney disease. Shilajit has been associated with uric-acid elevations in safety reviews.
- The 'shilajit boosts testosterone' claim viral on TikTok rests almost entirely on ONE small, manufacturer-funded RCT (Pandit 2016, n=75) in men aged 45–55 with low-normal baseline T. There is no RCT in healthy young men. Extrapolating a +20% T result across decades and baseline-T strata is not supported by the trial data.
- Nearly every positive shilajit RCT is industry-funded by Natreon, the producer of PrimaVie. The signal is directionally consistent across small trials, but independent replication outside Natreon-affiliated research is limited.
- Brand quality matters more for shilajit than for almost any other supplement. PrimaVie® (Natreon) is the standardised, heavy-metal-tested form used in essentially all of the cited RCTs. 'Raw resin', 'pure Himalayan tar', and unbranded shilajit powder without disclosed third-party testing are categorically different products from a safety standpoint.
Frequently asked
Does shilajit actually boost testosterone?
Honestly: yes, in one specific population, in one industry-funded trial. Pandit 2016 (n=75, double-blind RCT) showed 500 mg/day PrimaVie raised total testosterone ~20% over 90 days in healthy men aged 45–55. That is the entire human trial base for the testosterone claim. There is NO RCT in healthy young men, where the TikTok 'natural T booster' framing is aimed. If your baseline T is unmeasured, you have no way to know whether shilajit is doing anything for you. The signal is real in middle-aged men with low-normal baseline T; the extrapolation to young adults is unsupported.Is PrimaVie® shilajit worth paying more for vs raw resin?
Yes — and this is one of the few supplements where brand matters more than dose. Every positive shilajit RCT (Pandit 2016, Biswas 2010, Keller 2019, Das 2016) used purified, standardised material — almost always PrimaVie® from Natreon, standardised to fulvic-acid content with published heavy-metal certificates of analysis. Raw resin and unbranded powder from anonymous suppliers have repeatedly tested over regulatory limits for lead, arsenic, and mercury. This is not a 'premium-vs-budget' decision; it is a 'safe-vs-unsafe' decision.What's the right dose of shilajit?
The trial-supported range is 250–500 mg/day of purified, standardised shilajit (typically PrimaVie®), usually split as 250 mg twice daily. Pandit 2016 used 500 mg/day for testosterone; Keller 2019 found the 500 mg dose stronger than 250 mg for strength recovery; Biswas 2010 used 200 mg/day for fertility. Higher doses (1,000–2,000 mg/day) have been studied short-term in safety contexts but offer no documented additional benefit. Above 500 mg/day there is no efficacy data and rising side-effect risk.How worried should I be about heavy metals in shilajit?
Very worried if you are using uncertified raw resin; minimally worried if you are using a properly purified, third-party tested product like PrimaVie® with a published certificate of analysis. Analytical surveys (Aldakheel 2022 and ConsumerLab testing) have repeatedly found commercial shilajit samples exceeding lead, arsenic, mercury, and nickel limits. This is the single most important quality-control decision in the shilajit category. If a product cannot show you a recent COA on heavy metals, do not take it.Can women take shilajit?
Almost certainly not in pregnancy, breastfeeding, or active attempts to conceive — there is no adequate human pregnancy safety data and the heavy-metal contamination risk in unpurified products makes the precautionary call straightforward. Outside of pregnancy, female use is essentially unstudied: virtually every shilajit RCT has been in men. There is no female-specific dose, no female-specific outcome data, and women with hemochromatosis or iron-storage disorders should avoid entirely. Use cautiously and only with purified, tested product if you choose to try it.What should I actually look for on a shilajit label?
Four things, all non-negotiable: (1) the word 'PrimaVie®' or equivalent named purified extract — not 'raw resin' or 'pure Himalayan shilajit', (2) a standardised fulvic-acid percentage (typically ≥50%), (3) a published certificate of analysis confirming heavy metals (lead, arsenic, mercury, cadmium) are below regulatory limits, and (4) a clinical dose of 250–500 mg of the standardised extract per serving. Products that meet all four are a small fraction of the shilajit market. Most don't, and they should not be purchased.How long does shilajit take to work?
The testosterone trial (Pandit 2016) ran 90 days; the fertility trial (Biswas 2010) ran 90 days; the strength trial (Keller 2019) ran 8 weeks. None reported same-day or same-week effects. If you start shilajit expecting to 'feel' something within a week, you will probably notice only placebo and the iron-rich aftertaste. Plan for an 8–12 week trial of a quality product, with baseline lab measurements (total testosterone, ferritin) before starting if hormones are the goal.
References
- 01Pandit S et al., 2016, Andrologia — Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers
- 02Biswas TK et al., 2010, Andrologia — Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia
- 03Keller JL et al., 2019, J Int Soc Sports Nutr — Effects of Shilajit supplementation on fatigue-induced decreases in muscular strength
- 04Das A et al., 2016, J Med Food — Human skeletal muscle transcriptome in response to oral Shilajit supplementation
- 05Stohs SJ, 2014, Phytotherapy Research — Safety and efficacy of shilajit (mumie, moomiyo)
- 06Aldakheel RK et al., 2022, Biological Trace Element Research — Quantification of nutritional and poisonous metals in commercial shilajit
- 07Carrasco-Gallardo C et al., 2012, Archives of Medical Research — Nutraceuticals and Alzheimer's disease: shilajit and fulvic acid
- 08Surapaneni DK et al., 2012, Journal of Ethnopharmacology — Shilajit attenuates behavioural symptoms of chronic fatigue in a rat model
- 09Guzmán-Martínez L et al., 2021, Journal of Alzheimer's Disease — BrainUp-10 in mild-to-moderate Alzheimer's disease
- 10Ministry of AYUSH, Government of India — Ayurvedic Pharmacopoeia and quality standards for Shilajit (Asphaltum)
- 11NIH National Center for Complementary and Integrative Health — Ayurvedic medicine background
Last reviewed2026-05-24